IN2014DN06739A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06739A
IN2014DN06739A IN6739DEN2014A IN2014DN06739A IN 2014DN06739 A IN2014DN06739 A IN 2014DN06739A IN 6739DEN2014 A IN6739DEN2014 A IN 6739DEN2014A IN 2014DN06739 A IN2014DN06739 A IN 2014DN06739A
Authority
IN
India
Prior art keywords
treatment
cryotherapy
lesions
sequential
relates
Prior art date
Application number
Inventor
Torsten Skov
Original Assignee
Leo Pharma As
Leo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As, Leo Lab Ltd filed Critical Leo Pharma As
Publication of IN2014DN06739A publication Critical patent/IN2014DN06739A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452—Skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention relates to the treatment of actinic keratosis (AK) lesions using sequential cryotherapy and field treatment with ingenol mebutate (e.g. PEP005 Gel).
IN6739DEN2014 2012-01-26 2013-01-25 IN2014DN06739A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591093P 2012-01-26 2012-01-26
US201361753779P 2013-01-17 2013-01-17
PCT/EP2013/051435 WO2013110756A1 (en) 2012-01-26 2013-01-25 Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis

Publications (1)

Publication Number Publication Date
IN2014DN06739A true IN2014DN06739A (en) 2015-05-22

Family

ID=47681847

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6739DEN2014 IN2014DN06739A (en) 2012-01-26 2013-01-25

Country Status (4)

Country Link
US (1) US20150025139A1 (en)
EP (1) EP2806869A1 (en)
IN (1) IN2014DN06739A (en)
WO (1) WO2013110756A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180104503A1 (en) 2016-10-15 2018-04-19 Michelle Wirtz Cold atmospheric plasma treatment of actinic keratosis and non-melanoma skin cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700350T1 (en) * 2010-04-16 2017-09-07 Leo Pharma As Orthorhombic crystalline ingenol mebutate

Also Published As

Publication number Publication date
EP2806869A1 (en) 2014-12-03
US20150025139A1 (en) 2015-01-22
WO2013110756A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
MX2016003129A (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1.
UA109271C2 (en) COMBINATION OF PHYTOCANABINOIDS AND THEMOSOLAMIDE FOR THE TREATMENT OF GLIOMA
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
CL2015003704A1 (en) Peptides and peptidomimetics in combination uses and treatments for the subpopulation of cancer patients
MX2020003096A (en) Pharmaceutical formulations of a hif hydroxylase inhibitor.
EP2979657A4 (en) Medical instrument and medical system
TWI563685B (en) Light source, device including light source, and/or methods of making the same
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
IL284347A (en) Geranium oil and its components for the treatment of degenerative diseases
EP3036226A4 (en) Inhibitors of human 12/15-lipoxygenase
EP4509616A3 (en) Use of cd36 to identify cancer subjects for treatment
EP3044229A4 (en) Novel peptides and analogs for use in the treatment of oral mucositis
ES3037618T3 (en) Proteins with diagnostic and therapeutic uses
EP3050884A4 (en) Novel chemical compounds (variants) and the use thereof to treat oncological diseases
EP3005935A4 (en) Medical display device and endoscopic surgery system
EP3060908A4 (en) Diagnosis and treatment of autoimmune diseases
GB201602663D0 (en) Medical instrument and application thereof
EP3081140A4 (en) Endoscope treatment instrument
EP3081183A4 (en) Treatment instrument and treatment system
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
PH12015500822A1 (en) Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of cbp/catenin
EP3037032A4 (en) Light source device and endoscope device
AR082436A1 (en) USE OF TERIFLUNOMIDE TO TREAT MULTIPLE SCLEROSIS
EP3087940A4 (en) Medical procedure instrument and medical procedure system
IN2014DN06739A (en)